Alzex Neuropharma Inc.
TRRI
$0.00
-$0.07-99.58%
OTC PK
| 06/30/2011 | 03/31/2011 | 09/30/2010 | 06/30/2010 | ||
|---|---|---|---|---|---|
| Revenue | 23.63% | 11.21% | -46.67% | -66.09% | |
| Total Other Revenue | 14.29% | -- | -40.00% | 3.70% | |
| Total Revenue | 23.58% | 10.50% | -46.66% | -66.00% | |
| Cost of Revenue | 22.12% | 13.36% | -48.06% | -63.73% | |
| Gross Profit | 33.51% | -43.09% | -30.23% | -76.08% | |
| SG&A Expenses | 76.83% | -57.36% | -52.45% | -67.51% | |
| Depreciation & Amortization | -5.70% | -9.40% | 60.22% | 60.22% | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 27.57% | 6.39% | -47.64% | -66.06% | |
| Operating Income | -145.42% | 45.02% | 86.15% | 67.61% | |
| Income Before Tax | -68.31% | 50.26% | 81.56% | 63.85% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -68.31% | 50.26% | 81.56% | 63.85% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -68.31% | 50.26% | 81.56% | 63.85% | |
| EBIT | -145.42% | 45.02% | 86.15% | 67.61% | |
| EBITDA | -826.09% | 84.50% | 90.30% | 106.13% | |
| EPS Basic | -- | -- | -- | -- | |
| Normalized Basic EPS | -- | -- | -- | -- | |
| EPS Diluted | -- | -- | -- | -- | |
| Normalized Diluted EPS | -- | -- | -- | -- | |
| Average Basic Shares Outstanding | -- | -- | -- | -- | |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |